© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#doravirine

Merck Will Study Lower Dose of Long-Acting Islatravir

The company will resume development of islatravir for HIV treatment but abandons monthly oral PrEP.

Clinical Trials for HIV Meds Under-Recruit Women and People of Color

Researchers compared the demographics of participants in randomized controlled trials for antiretrovirals with the global HIV population.

Pifeltro

Treatment: Merck’s Doravirine

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

Merck’s Experimental HIV Drug Doravirine Posts Promising 96-Week Results

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

Merck Applies to FDA for Approval of New HIV Med Doravirine

The new drug application is for doravirine as both an individual tablet and part of a combination tablet.

Doravirine Combo Is Effective and Has Fewer Side Effects Than Atripla

The new single-tablet NNRTI regimen was less likely than Atripla to cause neurological symptoms.

Merck’s Doravirine Treats HIV as Well as Norvir-Boosted Prezista

Used as a part of a multidrug HIV regimen, the investigational doravirine is also better for cholesterol levels than Norvir/Prezista.

Delstrigo

Advertisement

POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.